Iasibon

Active Ingredient:: Ibandronic Acid
Origin:: EU

Iasibon (Ibandronic Acid)

Q: What conditions is Iasibon used to treat?

Iasibon contains ibandronic acid, a bisphosphonate indicated for the treatment of postmenopausal osteoporosis and glucocorticoid‑induced osteoporosis. In these conditions it helps increase bone mineral density and lowers the risk of fractures by reducing bone resorption.

Q: How does ibandronic acid work in the body?

Ibandronic acid binds to hydroxyapatite on bone surfaces. When osteoclasts attach to the drug‑coated bone, the compound is internalized, disrupting the mevalonate pathway, which leads to loss of essential prenylated proteins and triggers osteoclast apoptosis. This reduces bone breakdown and helps maintain skeletal strength.

Q: What is the usual dose of Iasibon?

The specific dose and dosing schedule of Iasibon are determined by the prescribing clinician based on the patient’s medical condition, renal function, and other individual factors. Healthcare professionals follow approved prescribing information to set the appropriate regimen.

Q: Is Iasibon safe to use during pregnancy or breastfeeding?

The safety of ibandronic acid in pregnancy and lactation has not been established. It is generally advised to avoid use unless the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

Q: How do I order Iasibon from GNH India?

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials. After verification, the team provides pricing, availability, shipping details (including any cold‑chain requirements), and assists with import documentation.

Q: How does Iasibon compare with other osteoporosis treatments?

Iasibon belongs to the bisphosphonate class, similar to alendronate and risedronate, but it has a longer dosing interval and a high affinity for bone mineral. Compared with selective estrogen receptor modulators or denosumab, ibandronic acid is taken orally and does not require injection, offering a convenient option for many patients while delivering comparable fracture‑risk reduction.

Q: What are the recommended storage conditions for Iasibon?

Iasibon tablets should be stored at room temperature, below 25 °C. Keep them in the original packaging to protect from moisture and light. Do not store in bathrooms or near heat sources, and keep out of reach of children.

Q: How is Iasibon administered?

Iasibon is taken orally, usually as a single tablet. The tablet should be swallowed with a full glass of water on an empty stomach, and the patient should remain upright for at least 30 minutes before lying down or eating to minimize esophageal irritation.

Q: What are the most serious risks associated with Iasibon?

Serious risks include osteonecrosis of the jaw, atypical femur fractures, severe renal impairment, and acute esophageal ulceration or perforation. Patients should be monitored for persistent jaw pain, unexplained thigh or groin pain, sudden changes in kidney function, and any severe gastrointestinal symptoms.

Q: Who should not use Iasibon?

Iasibon is contraindicated in patients with known hypersensitivity to ibandronic acid or other bisphosphonates, those with severe renal impairment (eGFR <30 mL/min), and individuals with esophageal abnormalities that delay emptying. It should also be avoided in patients who cannot remain upright for 30 minutes after dosing.

Ibandronic Acid, the active ingredient in Iasibon, is a bisphosphonate presented as an oral tablet for oral use. It is indicated for the treatment of postmenopausal osteoporosis and glucocorticoid‑induced osteoporosis in adults.

GNH India supplies Iasibon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Pharmathen S.A.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Iasibon is a bisphosphonate that acts on bone‑remodeling disorders to improve skeletal strength.
Postmenopausal osteoporosis: increases bone mineral density and reduces the risk of vertebral and non‑vertebral fractures.
Glucocorticoid‑induced osteoporosis: counteracts steroid‑related bone loss and helps maintain bone strength.

How It Works

Ibandronic Acid binds selectively to hydroxyapatite crystals on bone surfaces, especially at sites of active remodeling. When osteoclasts attach to the drug‑coated bone, it is internalized, disrupting the mevalonate pathway, leading to loss of prenylated proteins and ultimately inducing osteoclast apoptosis, thereby reducing bone resorption.

Side Effects

Iasibon may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

Upper gastrointestinal irritation or discomfort
Nausea or dyspepsia
Musculoskeletal pain, especially in the back or joints
Headache
Transient fever or flu‑like symptoms after the first dose
Esophageal irritation if not taken correctly

Serious or Rare Side Effects

Osteonecrosis of the jaw (ONJ)
Atypical subtrochanteric or femoral shaft fractures
Severe hypersensitivity reactions, including rash or anaphylaxis
Acute renal impairment or failure
Severe esophageal ulceration or perforation
Persistent, unexplained bone pain

Precautions & Warnings

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and counsel on proper administration.

Renal function assessment: avoid use in severe renal impairment (eGFR <30 mL/min).
Calcium and vitamin D status: ensure adequate supplementation to reduce hypocalcemia risk.
Administration technique: swallow tablet with a full glass of water and remain upright for at least 30 minutes.
Concomitant NSAIDs or steroids: monitor for increased gastrointestinal irritation.
Dental health: perform dental examination before starting and avoid invasive procedures during treatment.
Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Iasibon can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

Antacids or supplements containing calcium, magnesium, aluminum, or iron within 30 minutes of dosing.
Other bisphosphonates or bone‑active agents taken concurrently.
High‑dose systemic corticosteroids that may exacerbate gastrointestinal risk.
Nephrotoxic agents (e.g., aminoglycosides, amphotericin B) in patients with compromised renal function.
Concomitant use of potent NSAIDs increasing risk of upper GI ulceration.

Moderate Interactions (Monitor Closely)

Vitamin D supplementation: monitor serum levels to avoid hypercalcemia.
Warfarin or other anticoagulants: check INR more frequently.
Thiazide diuretics: watch for changes in calcium balance.
Oral contraceptives or hormone replacement therapy: observe for any alteration in bone turnover markers.

Frequently Asked Questions

Iasibon contains ibandronic acid, a bisphosphonate indicated for the treatment of postmenopausal osteoporosis and glucocorticoid‑induced osteoporosis. In these conditions it helps increase bone mineral density and lowers the risk of fractures by reducing bone resorption.

Ibandronic acid binds to hydroxyapatite on bone surfaces. When osteoclasts attach to the drug‑coated bone, the compound is internalized, disrupting the mevalonate pathway, which leads to loss of essential prenylated proteins and triggers osteoclast apoptosis. This reduces bone breakdown and helps maintain skeletal strength.

The specific dose and dosing schedule of Iasibon are determined by the prescribing clinician based on the patient’s medical condition, renal function, and other individual factors. Healthcare professionals follow approved prescribing information to set the appropriate regimen.

The safety of ibandronic acid in pregnancy and lactation has not been established. It is generally advised to avoid use unless the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials. After verification, the team provides pricing, availability, shipping details (including any cold‑chain requirements), and assists with import documentation.

Iasibon belongs to the bisphosphonate class, similar to alendronate and risedronate, but it has a longer dosing interval and a high affinity for bone mineral. Compared with selective estrogen receptor modulators or denosumab, ibandronic acid is taken orally and does not require injection, offering a convenient option for many patients while delivering comparable fracture‑risk reduction.

Iasibon tablets should be stored at room temperature, below 25 °C. Keep them in the original packaging to protect from moisture and light. Do not store in bathrooms or near heat sources, and keep out of reach of children.

Iasibon is taken orally, usually as a single tablet. The tablet should be swallowed with a full glass of water on an empty stomach, and the patient should remain upright for at least 30 minutes before lying down or eating to minimize esophageal irritation.

Serious risks include osteonecrosis of the jaw, atypical femur fractures, severe renal impairment, and acute esophageal ulceration or perforation. Patients should be monitored for persistent jaw pain, unexplained thigh or groin pain, sudden changes in kidney function, and any severe gastrointestinal symptoms.

Iasibon is contraindicated in patients with known hypersensitivity to ibandronic acid or other bisphosphonates, those with severe renal impairment (eGFR <30 mL/min), and individuals with esophageal abnormalities that delay emptying. It should also be avoided in patients who cannot remain upright for 30 minutes after dosing.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 31 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.